Half-year report · Q2
4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.5bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥46.7bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥36.1bn | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥2.6bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥24.6bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥2.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥20.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥24.7bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥17.9bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥17.9bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥78.5bn | at 2025-06-30 | Cons. | Assets IFRS |
| Total assets | ¥92.8bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥95.9bn | at 2024-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥24.9bn | at 2025-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥36.0bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥53.7bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥58.8bn | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥53.7bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥56.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥58.8bn | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥48.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥25.5bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥11.0bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥23.8bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥2.7bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥8.4bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥10.0bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥115.85 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥138.3 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥115.68 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥138.11 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 68.3% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.3% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥453m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥453m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥761m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥761m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥3.0bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥7.8bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥436m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥9.0bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥2.6bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥178m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥178m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥28.5bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥28.5bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥24.7bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥7.8bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥7.7bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥178m |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥47m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥36.3bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥36.1bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥178m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥24.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 582
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 130010400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 130010400 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 130010400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 130010400 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 17373000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1336 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 13285000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1022 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 12350000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0950 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 11930000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0918 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 4724000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0363 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 4489000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0345 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 4156000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0320 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 2419000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0186 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 2352000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0181 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 1976000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0152 | |
| Number of shares held | CurrentQuarterInstant | 75058000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5773 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 300 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1300101 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 130010100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 130010400 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 1300101 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0000 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 48117933000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 33328222000 | JPY |
| Trade and other receivables ca IFRS | Prior1YearInstant | 5282889000 | JPY |
| Trade and other receivables ca IFRS | CurrentQuarterInstant | 4495792000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 6246000 | JPY |
| Other financial assets ca IFRS | CurrentQuarterInstant | 6247000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |